Patents by Inventor Bianka Prinz

Bianka Prinz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE
    Publication number: 20220089760
    Abstract: Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.
    Type: Application
    Filed: December 6, 2021
    Publication date: March 24, 2022
    Inventors: Mitchell Bigelow, Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz, Ronnie Wei, Daniel Fallon, Steven O'Neil
  • Anti-CD112R compositions and methods
    Patent number: 11279758
    Abstract: The invention provides anti-CD112R antibody compositions and their use in treating cancer.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: March 22, 2022
    Assignee: Surface Oncology, Inc.
    Inventors: Bianka Prinz, Nadthakarn Boland, Kevin Schutz, John Bukowski, Jennifer Symonds, James Mohan, Marisella Panduro Sicheva
  • CD38 antibody
    Patent number: 11236173
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: February 1, 2022
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
  • Anti-CD112R compositions and methods
    Patent number: 11214619
    Abstract: The invention provides anti-CD112R antibody compositions and their use in treating cancer.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: January 4, 2022
    Assignee: SURFACE ONCOLOGY, INC.
    Inventors: Bianka Prinz, Nadthakarn Boland, Kevin Schutz, John Bukowski, Jennifer Symonds, James Mohan, Marisella Panduro Sicheva
  • Antibodies That Bind CD39 and Uses Thereof
    Publication number: 20210363268
    Abstract: The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.
    Type: Application
    Filed: March 13, 2019
    Publication date: November 25, 2021
    Applicant: Surface Oncology, Inc.
    Inventors: Scott CHAPPEL, Andrew LAKE, Michael WARREN, Austin DULAK, Erik DEVEREAUX, Pamela M. HOLLAND, Tauqeer ZAIDI, Matthew RAUSCH, Bianka Prinz, Nels P. NIELSON, Sonia DAS
  • PROTEIN BINDING NKG2D, CD16 AND A FIBROBLAST ACTIVATION PROTEIN
    Publication number: 20210363261
    Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD16, and fibroblast activation protein (FAP) are described, as well as pharmaceutical compositions and therapeutic methods of the multi-specific binding proteins useful for the treatment of cancer, autoimmune disease, or fibrosis.
    Type: Application
    Filed: May 16, 2019
    Publication date: November 25, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Jinyan Du, Asya Grinberg, William Haney, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • ANTI-CD19 ANTIBODIES AND USES THEROF
    Publication number: 20210347888
    Abstract: Antibodies, fragments thereof and fusion proteins that specifically bind to CD19, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 11, 2021
    Inventors: Daniel Tavares, Bianka Prinz, James Geoghegan
  • MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE
    Publication number: 20210317223
    Abstract: Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.
    Type: Application
    Filed: August 8, 2019
    Publication date: October 14, 2021
    Inventors: Mitchell Bigelow, Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • SURFACE DISPLAY OF WHOLE ANTIBODIES IN EUKARYOTES
    Publication number: 20210317441
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Application
    Filed: June 10, 2021
    Publication date: October 14, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
    Publication number: 20210292420
    Abstract: Multi-specific binding proteins that bind the NKG2D receptor, CD16, and a tumor-associated antigen are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: March 2, 2021
    Publication date: September 23, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • CD38 MODULATING ANTIBODY AGENTS
    Publication number: 20210277138
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: June 8, 2018
    Publication date: September 9, 2021
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenchea Corzo, Hemanta Baruah, Bianka Prinz
  • Anti-TIGIT Antibodies
    Publication number: 20210269527
    Abstract: Isolated antibodies or antigen-binding portions that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT.
    Type: Application
    Filed: October 28, 2020
    Publication date: September 2, 2021
    Applicant: Seagen Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz
  • PROTEINS BINDING NKG2D, CD16, AND EGFR, CCR4, OR PD-L1
    Publication number: 20210261668
    Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD16, and a tumor-associated antigen selected from EGFR, HLA-E, CCR4, and PD-L1 are described, as well pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: March 1, 2021
    Publication date: August 26, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Jinyan Du, Asya Grinberg, William Haney, Dhruv Kam Sethi, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • Anti-CD112R Compositions and Methods
    Publication number: 20210253699
    Abstract: The invention provides anti-CD112R antibody compositions and their use in treating cancer.
    Type: Application
    Filed: July 19, 2019
    Publication date: August 19, 2021
    Applicant: Surface Oncology, Inc.
    Inventors: Bianka Prinz, Nadthakarn Boland, Kevin Schutz, John Bukowski, Jennifer Symonds, James Mohan, Marisella Panduro Sicheva
  • PROTEINS BINDING NKG2D, CD16 AND P-CADHERIN
    Publication number: 20210238290
    Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD16, and P-cadherin, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: May 6, 2019
    Publication date: August 5, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Jinyan Du, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • PROTEINS BINDING NKG2D, CD16 AND AN ANTIGEN ASSOCIATED WITH TUMORS, MDSCS AND/OR TAMS
    Publication number: 20210221894
    Abstract: Multi-specific binding proteins that bind the NKG2D receptor, CD 16, and a tumor-associated antigen on tumor cells, or an antigen on myeloid-derived suppressor cells or tumor-associated macrophages are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: April 3, 2019
    Publication date: July 22, 2021
    Inventors: Mitchell Bigelow, Gregory P. Chang, Ann F. Cheung, Jean-Marie Cuillerot, Jinyan Du, Asya Grinberg, William Haney, Steven O'Neil, Nicolai Wagtmann, Bradley M. Lunde, Bianka Prinz
  • ANTIBODY MOLECULES TO CD73 AND USES THEREOF
    Publication number: 20210214459
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 15, 2021
    Inventors: Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Kulandayan Kasi Subramanian, Marie-Louise Fjaellskog, John Delmas Venable, III, Bianka Prinz, Jerry M. Thomas, Andrew Lake, Scott Chappel, Pamela Holland, Michael Warren, Alison Paterson, Rachel W. O'Connor, Michael Gladstone, Jonathan Hill, Christine Miller
  • MULTI-SPECIFIC BINDING PROTEINS AND IMPROVEMENTS THEREON
    Publication number: 20210214436
    Abstract: The invention provides improvements on single-chain variable fragment (scFv) antibodies, multi-specific binding proteins, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.
    Type: Application
    Filed: May 28, 2019
    Publication date: July 15, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Jinyan Du, Daniel Fallon, Asya Grinberg, William Haney, Steven O'Neil, Ronnie Wei, Bradley M. Lunde, Bianka Prinz
  • DUAL SPECIFICITY ANTIBODIES TO PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR
    Publication number: 20210214445
    Abstract: The present disclosure is directed to dual specificity antibodies which may bind to PD-L1 or PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1 or PD-L2.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 15, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael A. CURRAN, Ashvin R. JAISWAL, Dongxing ZHA, Kui VOO, Carlo TONIATTI, Bianka PRINZ, Nga Rewa HOUSTON, Eric KRAULAND
  • PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
    Publication number: 20210206859
    Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen (e.g, B7-H3, L1CAM, FLT1, KDR, TNC, TNN, CSPG4, BST1, SELF, CD200, INSR (HHF5), ITGA6, MELTF, PECAM1, or SLC1A5) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: August 8, 2019
    Publication date: July 8, 2021
    Inventors: Gregory P. Chang, Ann F. Cheung, Jinyan Du, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz